Lion’s Mane: Memory, Mood and the Wider Research

What is lion’s mane?

Lion’s mane is Hericium erinaceus, an edible fungus sold as food, dried powder and extracts. The visible mushroom is the fruiting body; mycelium is the fungus's threadlike growing network. Human studies have tested both, including a specially grown mycelium enriched with a compound called erinacine A.

Its appeal as a memory supplement has some human research behind it. Small trials have found improvements on particular cognitive tests, especially in older adults, but results change with the population, preparation and test. In healthy younger adults, faster performance on one task has appeared alongside unchanged or worse results on others.

From food and traditional use to modern supplements

Lion’s mane has a place in East Asian cuisine as well as medicine. Memorial Sloan Kettering’s account^[1] describes the mushroom eaten raw, dried or cooked and traditional medical uses that include stress, anxiety and depression. That history concerns varied food and medicinal preparations. The measured erinacine A products used in recent trials are specific modern ingredients.

Modern research has spread beyond memory: investigators have tested mood and sleep, hearing, and changes in gut microbes.

What people take lion’s mane for

Table note: “Review pending” means our assessment of the sources is incomplete; it does not mean the studies found no effect. The research-verdict column summarizes the findings. New or worsening memory problems deserve an assessment of their cause. For someone who is otherwise healthy and wants more focus, the younger-adult studies are the closer comparison.

Fruiting body, mycelium and extracts

Fruiting-body powder is dried mushroom material. The 2019 Saitsu trial used that preparation. An extract is material obtained by processing the mushroom; the amount on the label may refer to the extract itself, while a separate ratio describes the starting material used to make it. A 10:1 ratio describes 10 units of starting mushroom for each unit of extract.

Mycelium also has human research. The Alzheimer's pilot used mycelia enriched to a stated erinacine A concentration. That specific preparation is a reason to distinguish products carefully, rather than automatically treating all mycelium as inferior or all fruiting-body products as proven.

There is no official nutritional requirement for lion’s mane; the gram amounts in these studies describe particular experiments.

No head-to-head comparison in the trials discussed here establishes which of these preparations works best. A product's fungal part and extraction details tell you what it contains; the clinical result still depends on the evidence for that preparation and purpose.

What should you look for on the label?

First check the species: Hericium erinaceus. Then find the fungal part, whether it is powder or extract, the amount per serving and how many capsules make that serving. In a mushroom blend, the blend's total weight may conceal how much lion's mane is actually present.

A beta-glucan percentage describes one group of mushroom compounds. It is not the same measurement as erinacine A, the compound specified in the Alzheimer's pilot. Likewise, an extract ratio does not tell you the erinacine A content.

The claims worth examining are specific ones. “Supports memory” can refer to a favorable screening score in older adults, whereas “instant focus” needs evidence from single-dose studies in healthy people. Those studies give different answers, as the science below shows.

What are the drawbacks?

The Alzheimer's trial followed participants for 49 weeks, with 41 completers; that is useful tolerability information but a small sample for detecting uncommon problems. ^[2]

A 2003 case report^[3] described severe respiratory illness in a man taking a commercial lion’s mane extract, with testing that supported a possible reaction. A single report cannot estimate how often this happens or establish the risk of other preparations. A new rash, wheeze or breathing problem after a supplement is a reason to stop it and seek appropriate care; severe breathing difficulty needs urgent help.

What have memory and attention trials found?

Mild cognitive impairment: the original powder study

The 2009 Mori trial^[4] randomized 30 adults aged 50–80 with mild cognitive impairment to lion's mane or placebo. Participants took four 250 mg tablets three times a day for 16 weeks; the tablets contained 96% dried mushroom powder.

Scores on a cognitive scale favored lion's mane at weeks 8, 12 and 16. Scores in the mushroom group fell again during the four weeks after treatment stopped. This is the basis for much of the early memory interest, but the study was small and the abstract does not quantify the score advantage. Authors included researchers affiliated with Hokuto Corporation's mushroom laboratory.

The post-treatment decline raises a real question about persistence. It does not establish how long a person should continue taking a supplement, or whether continuing would preserve the benefit over years.

Healthy older adults: a small score difference

Saitsu's 2019 study^[5] recruited 34 healthy adults over 50 and analyzed 31. It used four supplements daily, each containing 0.8 g fruiting-body powder: 3.2 g/day, for 12 weeks. Three participants were excluded from analysis, including one with a low initial cognitive score.

At the end, the lion's-mane group averaged 30 out of 30 on the Mini-Mental State Examination, a brief cognitive screening test, compared with 29.53 on placebo. Both groups had started near the top of the scale. The difference was statistically significant, but less than half a point. Tests of visual memory and learning word pairs showed no significant benefit.

That combination is more informative than the paper's broad dementia-prevention language: a small change on one screening scale, with no corresponding advantage on the two other tests.

Another older-adult trial: the analysis changes the answer

A 2024 trial by Černelič Bizjak and colleagues^[6] analyzed 33 healthy adults aged 55–75 after eight weeks. Six capsules supplied 3 g/day of a proprietary cultivated and extracted preparation, with 3.44 mg of erinacine A. Ordinary comparisons of cognitive scores and their changes did not show a benefit. A model adjusting for starting score, age and sex favored treatment on a perception-speed test; further models that included a stool protein called CHI3L1 favored both pattern matching and completing visual sequences. This protein measurement is separate from the gut-bacteria diversity results below.

This is a tentative result whose interpretation depends on the analysis. The preparation came from MycoMedica, which supplied the capsules and had an author on the paper. The study also measured gut microbes, discussed below.

Alzheimer's trial: better daily function without a clear cognitive advantage

Li and colleagues' 2020 pilot^[2] enrolled people who already had mild Alzheimer's disease. Of 49 randomized participants, 41 completed the study. Treatment was three 350 mg mycelia capsules daily for 49 weeks, standardized to 5 mg of erinacine A per gram. That supplied 1.05 g mycelia and, calculated from the stated concentration, 5.25 mg erinacine A per day.

At week 49, a scale of instrumental daily activities, such as managing everyday tasks, favored mycelia over placebo. However, neither of the two cognitive scales showed a statistically significant between-group difference. The widely repeated improvement in the Mini-Mental State Examination was a comparison with the treated group's own starting score.

Grape King Bio supplied the material and employed several authors. This was a preliminary study of function in existing disease, not a trial counting how many healthy people avoided Alzheimer's.

Healthy younger adults: mixed results across cognitive tasks

In Docherty's 2023 pilot^[7], healthy adults aged 18–45 took a proprietary mushroom complex at 1.8 g/day or placebo. There were 43 people in the single-dose analysis and 41 in the four-week analysis. One hour after a dose, performance on the Stroop task, which tests handling conflicting information, was faster. Immediate word recall moved in the opposite direction: the lion's-mane group recalled fewer correct words after dosing. After four weeks, delayed word recall improved in the placebo group. Sempera Organics supplied the capsules; the authors reported no additional external funding.

Two other trials help put that result in perspective. In Grozier 2022^[8], 24 college-age participants completed four weeks of 10 g/day mushroom in muffins or placebo muffins. The measured cognition outcomes showed no significant supplementation effect; measures of switching between fat and carbohydrate fuels during exercise were also unchanged. More mushroom did not produce a clear result in that experiment.

In La Monica 2023^[9], 40 adults completed a crossover experiment that included a single 1 g dose of fruiting-body material. The reported lion's-mane reaction-time improvements included comparisons with earlier testing in the same session, rather than clear advantages over placebo. Applied Food Sciences partly funded the study. Its positive abstract should be read alongside those actual comparisons.

A 2025 crossover trial by Surendran^[10] tested 3 g of a 10:1 fruiting-body extract in 18 healthy adults aged 18–35. At 90 minutes, the overall cognition and mood measures did not significantly improve compared with placebo. Exploratory results on individual tasks were mixed: performance improved on a pegboard task testing coordinated hand movement, but was worse than placebo on the Flanker task, which tests handling distracting information. These task findings did not establish an overall cognitive benefit. Two authors worked for a drinks company using lion's mane in its products; the company also contributed toward the publication fee.

These studies leave a plausible research question about individual tasks, but no dependable expectation of better concentration or memory throughout a working day.

The 2026 studies: one attention signal, several unchanged outcomes

A new randomized study^[11] tested 2 g/day of fruiting body plus mycelial biomass in adults aged 40–75 who reported cognitive difficulties. Its full preprint^[12] reports 150 randomized participants, 120 completers and 109 included in the analysis after eight weeks. These are two versions of the same study.

Improvement over time favored lion’s mane on Juggle Factor, an attention and working-memory task. The combined cognitive score and several other tasks did not differ. Sleep quality, restedness and mood improved faster with treatment, while motivation improved faster with placebo. M2 Ingredients funded the trial, supplied the product and had authors involved. The finding supports a focused research lead; it does not show a broad improvement across cognition.

In a separate 2026 pilot^[13], ten healthy adults took 2 g/day of fruiting body and mycelial biomass for four weeks. Tests of planning and mental control, and circulating brain-derived neurotrophic factor, a protein involved in nerve-cell biology, did not significantly change. There was no placebo group. This small negative pilot cannot settle efficacy, but it is part of the human evidence.

Mood and stress: tentative stress findings and no clear depression benefit

The four-week Docherty study also found a tentative reduction in subjective stress. The overall treatment test narrowly missed the usual statistical threshold, although a separate comparison at the last visit favored lion's mane. This is a lead for further research.

The earlier Nagano 2010 cookie trial^[14] randomized 30 women with various complaints but no specified diseases; 26 were analyzed. Four cookies supplied 2 g/day fruiting-body powder for four weeks. Depression scores improved from baseline in the mushroom group, but the change was not significantly better than placebo. Sleep scores also did not significantly differ.

Two individual complaint items, concerning motivation and palpitations, favored lion's mane. Anxiety, irritability and concentration items showed only trends. Aso Biotech supplied both sets of cookies and had two authors on the paper. Calling this a proven antidepressant effect would lose the main comparison.

A 2019 study in 77 adults with overweight or obesity^[15] adds a different comparison. Both groups followed a reduced-calorie diet; one also received 1.5 g/day of a mixture of mycelium and fruiting-body extract for eight weeks. There was no placebo. Reported mood and sleep improvements included comparisons within the supplement group, and one questionnaire was given only to that group. Overall depression scores did not show a clear between-group benefit, and the supplement did not add a demonstrated weight-loss advantage. AVD Reform supplied the product.

Where the nerve-growth claim comes from

Laboratory work^[16] found changes in nerve-growth-factor signaling in cells and mice. Nerve growth factor helps support nerve cells, which explains the scientific interest. The human trials above measured test scores, symptoms and daily function. They have not demonstrated that swallowing lion's mane regenerates damaged human nerves.

Hearing: a subgroup finding after negative overall comparisons

An eight-month trial in adults with hearing loss^[17] randomized 80 people aged 50–79; 59 finished. The treatment supplied 2 g/day of enriched mycelia and 10 mg of erinacine A mixed with honey, compared with matched honey-and-starch portions.

Overall, treatment did not improve the quietest sounds participants could hear or their speech-test results. Among participants aged 65 or older, selected tests favored mycelia for hearing quiet high-pitched sounds and recognizing speech at lower volumes. Speech discrimination—the ability to identify spoken words—did not show the same advantage. With substantial attrition and numerous subgroup measurements, that result needs confirmation. Grape King funded and supplied the preparation and had company-affiliated authors. These findings do not provide a reliable basis for expecting hearing to return.

Digestion and gut microbes: human experiments, limited clinical answers

In a 2021 pilot^[18], thirteen healthy adults took 3 g/day of lion’s mane powder grown in liquid culture for one week, with measurements before treatment and after a week off the supplement. Diversity within individual samples increased, but the overall comparison of microbial community patterns between periods was not statistically significant. These are different measures, called alpha and beta diversity respectively. There was no parallel placebo group, and participants with gastrointestinal disease were excluded.

In the 2024 older-adult trial, a measure of the variety and relative abundance of gut bacteria, called Shannon diversity, increased in the active group and declined with placebo after eight weeks; the changes differed between groups. Neither experiment established that those changes relieve digestive symptoms. A stool result alone cannot tell a reader whether abdominal pain, constipation or gastritis will improve.

Human digestive research also includes an older double-blind gastritis report^[19], whose results remain unavailable here.

Exercise research with a mushroom blend

Lion’s mane was one of six fungi in the 4 g/day PeakO2 blend studied in Hirsch’s exercise trial^[20]. The one-week comparisons were negative. A ten-person, three-week extension found a favorable oxygen-uptake comparison, while threshold and endurance comparisons remained nonsignificant. The blend’s individual mushroom amounts were not disclosed, so the study cannot isolate lion’s mane’s contribution. The cordyceps guide discusses this blend in more detail.

Bottom line

Lion’s mane has genuine human research behind its reputation, with selected cognitive and daily-function signals alongside many unchanged results. The newer attention study adds a useful lead, while mood, hearing and digestive claims still have substantial gaps.

The preparation and purpose matter together. Food, fruiting-body powder, mixed biomass and erinacine A-enriched mycelia are distinct comparisons. None of the studies establishes a dependable all-purpose brain or nerve treatment, and new memory or hearing problems deserve evaluation of their cause.

Help us improve this article

Spotted an error or found a source we should consider? Tell us which part of this article needs another look and include a link if you have one. Please leave out personal health details and lab results; we can’t answer individual medical questions.

Your name

Email address

What would you like to share?Select a topicCorrectionSource or research suggestionArticle requestAccessibility issueBusiness inquirySomething else

Your message

Continue to email →Email us directly